FRE.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:35):

Stats
Dagens volum	659 677
Gjennomsnittsvolum	1.15M
Markedsverdi	15.33B
EPS	€0 ( 2024-02-20 )
Neste inntjeningsdato	( €0.700 ) 2024-05-07
Last Dividend	€0.920 ( 2023-05-18 )
Next Dividend	€0 ( N/A )
P/E	43.19
ATR14	€0.0100 (0.04%)

Volum Korrelasjon

Lang: 0.07 (neutral)

Kort: 0.72 (moderate)

Signal:(49.053) Neutral

Fresenius SE & Co KGaA Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Fresenius SE & Co KGaA Korrelasjon - Valuta/Råvare

0.53
( weak )

0.48
( neutral )

0.00
( neutral )

0.59
( weak )

0.00
( neutral )

-0.57
( weak negative )

Fresenius SE & Co KGaA Økonomi

Annual	2023
Omsetning:	€22.30B
Bruttogevinst:	€5.06B (22.68 %)
EPS:	€-1.050

FY	2023
Omsetning:	€22.30B
Bruttogevinst:	€5.06B (22.68 %)
EPS:	€-1.050

FY	2022
Omsetning:	€40.84B
Bruttogevinst:	€10.73B (26.26 %)
EPS:	€2.44

FY	2021
Omsetning:	€37.52B
Bruttogevinst:	€10.31B (27.48 %)
EPS:	€3.26

Financial Reports:

No articles found.

Fresenius SE & Co KGaA Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€0.920 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Fresenius SE & Co KGaA Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 6.12 - average (70.81%) | Divividend Growth Potential Score: 2.35 - Decrease likely (52.95%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.512	2000-06-09
Last Dividend	€0.920	2023-05-18
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	25	--
Total Paid Out	€12.51	--
Avg. Dividend % Per Year	0.00%	--
Score	2.02	--
Div. Sustainability Score	6.12
Div.Growth Potential Score	2.35
Div. Directional Score	4.23	--

Next Divdend (Est)
(2025-03-19)

€0.964 Estimate 3.15 %

Dividend Stability

0.25 Very Poor

Dividend Score

2.02

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
IXX.DE	Ex Dividend Knight	2023-05-26	Annually	0.00%
SZG.DE	Ex Dividend Junior	2023-05-26	Annually	0.00%
DBK.DE	Ex Dividend Junior	2023-05-18	Sporadic	0.00%
MBG.DE	Ex Dividend Knight	2023-05-04	Annually	0.00%
47T.F	Ex Dividend Knight	2023-09-06	Annually	0.00%
VOS.DE	Ex Dividend Junior	2023-05-25	Sporadic	0.00%
EUZ.DE	Ex Dividend Knight	2023-06-08	Annually	0.00%
OEWA.DE	Ex Dividend Knight	2023-05-02	Annually	0.00%
ALD.DE	Ex Dividend Knight	2023-08-10	Quarterly	0.00%
HAG.DE	Ex Dividend Junior	2023-05-15	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.0187	1.500	-0.374	-0.561	[0 - 0.5]
returnOnAssetsTTM	-0.0131	1.200	-0.437	-0.525	[0 - 0.3]
returnOnEquityTTM	-0.0298	1.500	-1.443	-2.16	[0.1 - 1]
payoutRatioTTM	-2.07	-1.000	-10.00	10.00	[0 - 1]
currentRatioTTM	1.342	0.800	8.29	6.63	[1 - 3]
quickRatioTTM	0.728	0.800	-0.425	-0.340	[0.8 - 2.5]
cashRatioTTM	0.245	1.500	9.75	10.00	[0.2 - 2]
debtRatioTTM	0.350	-1.500	4.17	-6.26	[0 - 0.6]
interestCoverageTTM	2.53	1.000	-0.174	-0.174	[3 - 30]
operatingCashFlowPerShareTTM	7.91	2.00	7.36	10.00	[0 - 30]
freeCashFlowPerShareTTM	5.90	2.00	7.05	10.00	[0 - 20]
debtEquityRatioTTM	0.833	-1.500	6.67	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.233	1.000	9.45	9.45	[0.2 - 0.8]
operatingProfitMarginTTM	0.0554	1.000	-0.892	-0.892	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.281	1.000	9.55	9.55	[0.2 - 2]
assetTurnoverTTM	0.702	0.800	8.65	6.92	[0.5 - 2]
Total Score				6.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-25.80	1.000	-2.71	0	[1 - 100]
returnOnEquityTTM	-0.0298	2.50	-0.927	-2.16	[0.1 - 1.5]
freeCashFlowPerShareTTM	5.90	2.00	8.03	10.00	[0 - 30]
dividendYielPercentageTTM	3.38	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	7.91	2.00	7.36	10.00	[0 - 30]
payoutRatioTTM	-2.07	1.500	-10.00	10.00	[0 - 1]
pegRatioTTM	0.456	1.500	-0.295	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.140	1.000	8.99	0	[0.1 - 0.5]
Total Score				2.35

Fresenius SE & Co KGaA

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.